Department of Hematology, Ankara Bilkent City Hospital, Turkey.
Department of Hematology, Ankara Etlik City Hospital, Turkey.
Niger J Clin Pract. 2024 Aug 1;27(8):1012-1019. doi: 10.4103/njcp.njcp_726_23. Epub 2024 Aug 26.
Aim to investigate the prognostic value of neutrophil to lymphocyte ratio (NLR) at the time of diagnosis, which is an inexpensive and easily accessible parameter, compared to factors known as prognostic value (such as R-IPI and NCCN-IPI) in patients with diffuse large B-cell lymphoma (DLBCL).
Prognostic value of NLR at diagnosis in DLBCL.
A hundred (100) newly diagnosed DLBCL patients were included. The correlations between the NLR with clinical characteristics, treatment response, and survival were analyzed. The NLR cut-off value was taken at 3.5 accordıng to the receiver operating characteristic curve.
There were 53 patients with an NLR of 3.5 and 47 patients with an NLR < 3.5. Patients with NLR ≥ 3.5 had a complete response (CR) rate of 66.0% (n = 31/47), and patients with NLR < 3.5 had a CR rate of 98.1% (n = 51/52). The median progression-free survival (PFS) was 132.5 months (95%CI 103.1-162.0). PFS in the NLR ≥ 3.5 group (36 months) was significantly (P < 0.000) shorter than in the NLR < 3.5 group (185 months). The median overall survival (OS) for NLR ≥ 3.5 and NLR < 3.5 was 79.2 months (95% CI 51.6-106.8) and 197.8 months (95% CI 173.2-222.5), respectively. NLR ≥ 3.5 was associated with worse OS than NLR < 3.5 (P = 0.000). The high value of NLR (≥3.5) had lower treatment response rates, higher relapse, and death rates.
High NLR was associated with poor treatment response, PFS, and OS. NLR can be used as a cost-effective and easy-to-interpret prognostic marker in DLBCL patients.
目的在于研究中性粒细胞与淋巴细胞比值（NLR）在诊断时的预后价值，与已知的预后因素（如 R-IPI 和 NCCN-IPI）相比，NLR 是一种廉价且易于获取的参数，可用于弥漫性大 B 细胞淋巴瘤（DLBCL）患者。
NLR 在 DLBCL 患者诊断时的预后价值。
纳入 100 例新诊断的 DLBCL 患者。分析 NLR 与临床特征、治疗反应和生存之间的相关性。根据受试者工作特征曲线，将 NLR 截断值取为 3.5。
有 53 例患者 NLR 为 3.5，47 例患者 NLR < 3.5。NLR ≥ 3.5 的患者完全缓解（CR）率为 66.0%（n = 31/47），NLR < 3.5 的患者 CR 率为 98.1%（n = 51/52）。中位无进展生存期（PFS）为 132.5 个月（95%CI 103.1-162.0）。NLR ≥ 3.5 组的 PFS（36 个月）明显（P < 0.000）短于 NLR < 3.5 组（185 个月）。NLR ≥ 3.5 和 NLR < 3.5 的中位总生存期（OS）分别为 79.2 个月（95%CI 51.6-106.8）和 197.8 个月（95%CI 173.2-222.5）。NLR ≥ 3.5 与 NLR < 3.5 相比，OS 更差（P = 0.000）。NLR 较高（≥3.5）的患者治疗反应率较低，复发和死亡率较高。
高 NLR 与治疗反应不良、PFS 和 OS 相关。NLR 可作为 DLBCL 患者一种具有成本效益且易于解释的预后标志物。
